Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies
Ann Ranger(490 BioTech (United States)), Sha Mi(Biogen (United States))
Cited by 30
Related Papers
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
|The Lancet Neurology|2019|185
LINGO-1 Regulates Oligodendrocyte Differentiation through the Cytoplasmic Gelsolin Signaling Pathway
|Journal of Neuroscience|2017|42